The proteasome Inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

American Journal of Hematology

Volumn 84, Issue 1, 2009, Pages 6-14

  Pennisi, Angela ^a,b   Li, Xin ^a   Ling, Wen ^a   Khan, Sharmin ^a   Zangari, Maurizio ^a   Yaccoby, Shmuel ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c Myeloma Institute for Research and Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; MELPHALAN; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CELL; BONE DENSITY; BONE DISEASE; BONE REMODELING; CANCER INHIBITION; CELL COUNT; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG RESPONSE; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MORPHOMETRICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SCID MOUSE; TREATMENT RESPONSE; TUMOR GROWTH; X RAY;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; BORONIC ACIDS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; PROTEASE INHIBITORS; PYRAZINES; RABBITS;

EID: 58149478516     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21310     Document Type: Article

References (43)

1. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteociasts is the earnest critical event in the pathogenesis of human muitiple myeloma. J Clin Invest 1991;88:62-66.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655-1684.
3. Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003;44:1463-1467.
4. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
5. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
6. Markowitz GS, Fine PL, Stack Jl, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003:64:281-289.
7. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-4935.
8. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289-3294.
9. Stewart JP, Shaughnessy JD Jr. Role of osteoblast suppression in multiple myeloma. J Cell Biochem 2006;98:1-13.
10. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
11. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-1782.
12. Mukherjee S, Raje N, Schoonmaker JA, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008:118:491-504.
13. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-73.
14. Heider U, Kaiser M, Muller C, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006;77:233-238.
15. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2008;135:688-692.
16. Giuliani N, Morandi E Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-338.
17. Zavrski I, Krebbel H, Wildemann B, et al. Proteasome inhibitors abrogate osteodast differentiation and osteodast function. Biochem Biophys Res Commun 2005;333:200-205.
18. Oyajobi BO, Garrett IR, Gupta A, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease. Br J Haematol 2007; 139:434-438.
19. Pearse RN, Sordino EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581-11586.
20. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaiing antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J yed 2003;349:2483-2494.
21. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116:278-290.
22. Croucher Pi, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-3540.
23. Vanderkerken K, De Leenheer E. Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-289.
24. Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18:482-492.
25. Yaccoby S, Ling W. Zhan F. et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-2111.
26. Yata K, Yaccoby S. The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004;18:1891-1897.
27. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-2913.
28. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-3582.
29. Yaccoby S, Wezeman MJ, Zangari M, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006:91:192-199.
30. Yaccoby S, Pennisi A, Li X, et al. Atacicept (TACI-lg) inhibits growth of TACl (high) primary myeloma cells in SGID-hu mice and in coculture with osteociasts. Leukemia 2008;22:406-413.
31. Zangari M, Yaccoby S, Cavallo F, et al. Response to bortezomib and activation of osteobiasts in multiple myeloma. Clin Lymphoma Myeloma 2008;7: 109-114.
32. Li X, Pennisi A, Zhan F et al. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol 2007;138: 802-811.
33. Ge Y, Zhan F, Barlogie B, et al. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol 2006;133:83-92.
34. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: Myeloma-osteoclast interactions as a model. Cancer Res 2004; 64:2016-2023.
35. Qiang YW, Shaughnessy JD Jr., Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 2008;112: 374-382.
36. Edwards CM, Edwards JR, Lwin ST, et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008;111:2833-2842.
37. Bellido T, All AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003;278:50259-50272.
38. Richardson PG, Mitsiades C, Schlossman R, et al. New drugs for myeloma. Oncologist 2007;12:864-889.
39. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
40. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008; 112:159-168.
41. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996-5000.
42. Perrien OS, Akel NS, Edwards PK, et al. Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 2007; 148:1654-1665.
43. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 2005;11:7599-7806.